Dennis K. Galanakis, MD
Dennis K. Galanakis, MD
Associate Professor of Pathology and Medicine
Director of Blood Bank
University Hospital, Level 5
Stony Brook Medicine
Stony Brook, NY 11794-7530
Tel: (631) 444-2625
Fax: (631) 444-3137
Dr. Galanakis is Board Certified in Clinical Pathology (1978), with subspecialty expertise in Transfusion Medicine, Apheresis, and Coagulation. He has extensive experience as Director of a Fellowship training program in Transfusion Medicine since 1991. He regularly receives consultations from local and distant metropolitan area physicians for apheresis of patients with a variety of diseases. He has published many studies on fibrinogen and is particularly well known for his expertise in familial fibrinogen anomalies. Dr. Galanakis has pioneered a procedure that stops excessive bleeding from surgery by use of the patient’s own platelet rich plasma. Adaptations of this procedure have been successfully used to minimize transfusion in open heart surgery and in burn patients, and to treat seromas.
Dr. Galanakis is internationally known for his published studies of normal fibrinogen variants and of inherited fibrinogen disorders. He regularly receives requests to evaluate such families from physicians in different states and countries, and such evaluations at times result in benefit to these families. In particular, loss of pregnancy has been avoided in many instances with such disorders, as a result of recommendations emanating from his tests and evaluations of such families. He has also published basic studies on the structure/function relationships of fibrinogen and on interactions of fibrinogen with other proteins and platelets.
|Institution and Location||Degree||Year(s)||Field of Study|
|Wagner College, SI, NY||B.S.||1958||Biology|
|Univ. of Saskatchewan, Canada||M.D.||1962||Medicine|
|Positions and Employment:
||Rotating Intern: Meamonides Hospital, Brooklyn, NY|
||Resident in Internal Medicine, Manhattan VA Hospital|
|1965-67||Fellow in Clinical Hematology, NY Medical College|
|1968-70||Research Fellow in Coagulation (Medicine)|
|1975-77||Resident in Clinical Pathology, Downstate Medical Center, Brooklyn, NY|
||Marshall, H. and Nellie Alworth Scholarship|
||Best Freshman Scholarship, Wagner College|
||Member of Editorial Board, Thrombosis Research journal|
||Member of the Council of Human Blood and Transfusion Services of NY State Department of Health, Chair of the Council, 1998-2007
|2000||Fellow of American Heart Association|
||Distinguished Service Award, NYS Department of Health|
||Chancelor’s Award for Excellence in Faculty Service|
Peer Reviewed Publications:
Galanakis, D.K. and Mosesson, M.W. Evaluation of in vivo proteolysis (fibrinogenolysis) in prolonging the thrombin time of human umbilical cord fibrinogen. Blood 1976; 48:109.
Galanakis, D.K., Mosesson, M.W. and Stathakis, N.E. Human fibrinogen heterogeneities. distribution and charge characteristics of aa chains and aa remnants in plasma fibrinogen molecules. J Lab Clin Med 1978; 92:376.
Galanakis, D.K., Laurent, P., Janoff, A, Chung, S.I. Cigarette smoke contains anticoagulants against fibrin aggregation and factor xiiia in plasma. Science 1982; 217: 642-645.
Galanakis D.K. and M.W.Mosesson. The Aa chain composition of plasma fibrinogen catabolites. Thromb Res 1983; 15: 287.
Galanakis, D.K. and Mosesson, M.W. Human fibrinogen heterogeneities: determination of the major Aa chain derivatives in blood. Thromb Res 1983; 31: 403-413.
Galanakis, Dennis K., Lane, Bernard P., & Simon, Sanford R. Albumin Modulates lateral assembly of fibrin polymers: evidence of enhanced fine fibril formation and of unique synergism with fibrinogen. Biochemistry 1987; 26: 2389-2400.
Galanakis D.K., A. Henschen, E.I.Peerschke, and M. Kehl. Fibrinogen stony brook, a heterozygous aa 16arg-cys dysfibrinogenemia. Evaluation of Diminished Platelet Aggregation Support and of Enhanced Inhibition of Fibrin Assembly. J Clin Invest 1989; 84: 295-304.
Galanakis, D.K., Spitzer S., Scharrer I. An unique dysfibrinogenemic family: Aa 16Arg- Cys accompanied by lack of normal Aa chains in fibrinogen from two of the four probands. Blood Coag & Fibrinol 1993; 4 : 67-71.
Galanakis D.K. and B. Ghebrehiwet. A unique property of a plasma proteoglycan, the C1q inhibitor: anticoagulant state resulting from its binding to fibrinogen. J Clin Invest 1994; 93: 303-310.
Galanakis DK. Studies of plasma cryoprecipitation: major increase in fibrinogen yield by albumin enrichrment of plasma. Thromb Res 1995; 78: 303-313.
Galanakis DK, Nuovo G, Spitzer S, Kaplan C. Co-presence of fibrinogen mRNA and antigen in human trophoblasts in situ. Posible significance. Thromb Res 1996; 81: 263-269.
Grieninger G. Lu XH. Cao Y. Fu YP. Kudryk BJ. Galanakis DK. Hertzberg KM. Fib(420), the novel fibrinogen subclass - newborn levels are higher than adult. Blood. 1997; 90 :2609-2614.
Galanakis DK,Neerman-Arbez M, Scheiner T, Henschen A, Hubbs D, Nagaswami C, Weisel J. Homophenotypic Aa R16H Fibrinogen (Kingsport): Uniquely Altered Polymerization Associated with Slower Fibrinopeptide A than Fibrinopeptide B Release. Blood Coag & Fibrinol, 2007; 18:08: 731-737.
Galanakis DK, Neerman-Arbez M, Kudryk B, Henschen A. Decreased plasmin resistance by clots of a homophenotypic Aa R16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release). Blod Coag Fibrinol, 2010; 21:135-9.
Schachtrup C, Ryu JK, Helmrick MJ, Vagena E, Galanakis DK, Degen JL, Margolis RU, Akassoglou K. Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. J Neurosci, 2010 ;30 :5843-54.
Koo J, Rafailovich MH, Medved L,Tsurupa G, Kudryk BJ, Galanakis DK. Evaluation of Fibrinogen Self-assembly: Role of its αC Region. J Thromb Haemost, 2010; 8: 2727–35.